Jazz turns to AbCellera for T cell engagers in up to $4.1B partnership

AbCellera CEO Carl Hansen (L) and Jazz Pharmaceuticals' Joshua Allen June 17, 2026 07:00 AM EDT Deals Jazz turns to Ab­Cellera for T cell en­gagers against GI can­cers in up to $4.1B deal Kyle LaHucik Biotech Correspondent For much of its first decade, Cana­di­an an­ti­body de­vel­op­er Ab­Cellera signed part­ner­ship af­ter part­ner­ship, se­cur­ing 40 bio­phar­ma al­liances that led to more than a dozen … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER